ERBB2 and breast cancer: These results further suggest that 111In[In]-BnDTPA-trastuzumab may be a promising MAE-emitting RIT agent for treating brain metastases in patients with HER2-positive BC by employing MRIg-FUS-enhanced delivery into the brain.